drugset / Trial / NCT05143190
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
Phase 2
Completed
2 enrolled
Phoenix Tissue Repair, Inc.
Phoenix Tissue Repair, a BridgeBio company · collab
NaSingle-groupOpen-labelTreatment
Summary
A sub-set of patients who participated in PTR-01-002 will be enrolled in an open-label study, if they meet the study eligibility criteria.
Timeline
- Start
- 2021-12-02
- Primary completion
- 2022-06-20
- Completion
- 2022-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PTR-01 | Protein / enzyme biologic | 3 mg/kg | Intravenous |